NASDAQ · Financial Statements
Immunic, Inc. (IMUX) Financial Statements
$14.24
NASDAQ: IMUX
Market Cap $193.97M
Overview Financials Dividend Immunic, Inc. most recently reported annual revenue of $0, net profit of $-97.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-92.0M $-119.0M $-99.0M $-98.0M $-103.0M Net Profit $-93.0M $-120.0M $-94.0M $-101.0M $-97.0M EPS $-39.30 $-37.84 $-21.12 $-10.03 $-6.24 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $139.0M $128.0M $54.0M $41.0M $24.0M Total Liabilities $12.0M $14.0M $25.0M $22.0M $31.0M Cash $87.0M $107.0M $47.0M $36.0M $15.0M Borrowings $1.0M $2.0M $1.0M $1.0M $1.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-83.0M $-65.0M $-71.0M $-85.0M $-86.0M Investing Cash Flow $0 $-10.0M $9.0M $-1.0M $0 Financing Cash Flow $0 $0 $0 $0 $0 Net Cash Flow $-41.0M $20.0M $-60.0M $-11.0M $-20.0M Free Cash Flow $-83.0M $-65.0M $-71.0M $-85.0M $-86.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.04 EV / EBITDA -0.35 FCF Yield -45.39% Quick Ratio 5.05 Interest Coverage 0.00 Return 1Y 74.88% Return 3Y -41.94% Return 5Y -84.27%
Screens featuring this stock